Dale W. Garsed

TL;DR: The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.

TL;DR: It is shown that gene breakage commonly inactivates the tumour suppressors RB1, NF1, RAD51B and PTEN in HGSC, and contributes to acquired chemotherapy resistance.

TL;DR: Current available HRD tests are useful for predicting likely magnitude of benefit from PARPis but better biomarkers are urgently needed to better identify current homologous recombination proficiency status and stratify HGSC management.

TL;DR: In this article, the authors extensively characterize intra-tumor heterogeneity (ITH) across whole-genome sequences of 2,658 cancer samples spanning 38 cancer types and identify cancer type-specific subclonal patterns of driver gene mutations, fusions, structural variants, and copy number alterations.

TL;DR: The dynamic mutational processes underlying the life history of a special form of cancer mutation are investigated, including amplification terminates, and the neochromosome core is stabilized in linear form by telomere capture.